Last edition
News about "Kazia Therapeutics"
Kazia Expands Oncology Platform with First-in-Class SETDB1 Inhibitor
Kazia Therapeutics expands its oncology platform with a first-in-class SETDB1 inhibitor, leveraging an AI-driven epigenetic drug discovery engine for faster and scalable candidate development.
Kazia Therapeutics | 15/04/2026 | By News Bureau
Kazia Therapeutics Limited, a Sydney-based oncology-focused drug development company, has entered into an exclusive collaboration and in-licensing agreement with QIMR Berghofer to advance a pioneering PD-L1 degrader programme.
Kazia Therapeutics | 11/10/2025 | By Darshana | 173
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy